Brineura® (cerliponase alfa)
| Full Name | Brineura® (cerliponase alfa) |
| Drug | Brineura |
| Manufacturer | BioMarin Pharmaceutical Inc. |
| Route of Administration | Intraventricular |
| Site of Care | Healthcare Facility |
| Approved Indication | Indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency |
| Disease | Ceroid Lipofuscinosis (C2LN) |
| Therapeutic Area | Neurology |
| Enrollment Form Link | Enrollment Form |
| Phone Number | 800-240-9572 |
| Fax Number | 877-220-7581 |
| Product Website | brineura.com/hcp |